Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keisuke Shirai

Showing results (41-50 of 81) with videos related to

Pageof 9
Sort By:
American Journal of Clinical Oncology|October 21, 2009
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancerBree N Ruppert, John M Watkins, Keisuke Shirai, et al.
Japanese Journal of Radiology|June 30, 2010
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomesJohn M Watkins, John A Fortney, Amy E Wahlquist, et al.
Journal of Medical Imaging and Radiation Oncology|October 21, 2010
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survivalJohn M Watkins, Amy E Wahlquist, A Jason Zauls, et al.
Biomedicines|July 29, 2025
Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus InfectionAoi Kawamura, Shinya Abe, Keisuke Shirai, et al.
The American Journal of Surgical Pathology|May 16, 2019
Small and Isolated Immunohistochemistry-positive Cells in Melanoma Sentinel Lymph Nodes Are Associated With Disease-specific and Recurrence-free Survival Comparable to that of Sentinel Lymph Nodes Negative for MelanomaRobert E LeBlanc, Dorothea T Barton, Zhongze Li, et al.
Japanese Journal of Clinical Oncology|November 19, 2010
Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancerJohn M Watkins, Andris Jason Zauls, Patricia L Kearney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinomaChristopher J Herrem, Tomohide Tatsumi, Kathleen S Olson, et al.
Oral Oncology|January 17, 2015
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancerAntonio Jimeno, Julie E Bauman, Charles Weissman, et al.
Journal for Immunotherapy of Cancer|October 16, 2014
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case seriesSowmya Ravi, Kristen Spencer, Mary Ruisi, et al.
Cancers|August 23, 2020
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal MelanomaMerve Hasanov, Matthew J Rioth, Kari Kendra, et al.
Pageof 9

Showing results (41-50 of 81) with videos related to

Sort By:
Pageof 9
American Journal of Clinical Oncology|October 21, 2009
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancerBree N Ruppert, John M Watkins, Keisuke Shirai, et al.
Japanese Journal of Radiology|June 30, 2010
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomesJohn M Watkins, John A Fortney, Amy E Wahlquist, et al.
Journal of Medical Imaging and Radiation Oncology|October 21, 2010
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survivalJohn M Watkins, Amy E Wahlquist, A Jason Zauls, et al.
Biomedicines|July 29, 2025
Changes in Neutrophil Count During Valganciclovir Therapy for Symptomatic Congenital Cytomegalovirus InfectionAoi Kawamura, Shinya Abe, Keisuke Shirai, et al.
The American Journal of Surgical Pathology|May 16, 2019
Small and Isolated Immunohistochemistry-positive Cells in Melanoma Sentinel Lymph Nodes Are Associated With Disease-specific and Recurrence-free Survival Comparable to that of Sentinel Lymph Nodes Negative for MelanomaRobert E LeBlanc, Dorothea T Barton, Zhongze Li, et al.
Japanese Journal of Clinical Oncology|November 19, 2010
Toxicity, response rates and survival outcomes of induction cisplatin and irinotecan followed by concurrent cisplatin, irinotecan and radiotherapy for locally advanced esophageal cancerJohn M Watkins, Andris Jason Zauls, Patricia L Kearney, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 27, 2005
Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinomaChristopher J Herrem, Tomohide Tatsumi, Kathleen S Olson, et al.
Oral Oncology|January 17, 2015
A randomized, phase 2 trial of docetaxel with or without PX-866, an irreversible oral phosphatidylinositol 3-kinase inhibitor, in patients with relapsed or metastatic head and neck squamous cell cancerAntonio Jimeno, Julie E Bauman, Charles Weissman, et al.
Journal for Immunotherapy of Cancer|October 16, 2014
Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case seriesSowmya Ravi, Kristen Spencer, Mary Ruisi, et al.
Cancers|August 23, 2020
A Phase II Study of Glembatumumab Vedotin for Metastatic Uveal MelanomaMerve Hasanov, Matthew J Rioth, Kari Kendra, et al.
Pageof 9